:: Volume 7, Issue 4 (Special Issue: Policy Brief 2026) ::
J Mar Med 2026, 7(4): 77-80 Back to browse issues page
Biopharmaceuticals in Iran: Analyzing Achievements, Challenges, and Policy-Making
Mozafar Mohammadi , Mohammad Sadegh Hashemzadeh *
Nanobiotechnology Research Center, New Health Technologies Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran , msh.biotechnology@gmail.com
Abstract:   (914 Views)
The Iranian biopharmaceutical industry is currently experiencing a paradoxical situation. On one hand, it has emerged as a leading technological sector in the country, achieving notable successes such as partial self-sufficiency, the production of biosimilar drugs, and exports to regional markets. On the other hand, the industry faces deep structural challenges in policy-making, financing, regulatory frameworks, and innovation. This article examines the dual perspective of “achievements” versus “policy challenges” and, while providing an analysis of the current status, emphasizes the need to complete and strengthen the innovation ecosystem as a key strategic priority. Sustainable solutions lie not in a multitude of fragmented actions but in the establishment of a coherent, resilient, and efficient policy framework.
 
Keywords: Biopharmaceuticals, Biosimilars, Innovation ecosystem, National biotechnology roadmap
Full-Text [PDF 338 kb]   (611 Downloads)    
Type of Study: Policy Brief | Subject: Marine Medicine
Received: 2025/12/7 | Accepted: 2026/01/19 | Published: 2026/01/30



XML   Persian Abstract   Print



Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 7, Issue 4 (Special Issue: Policy Brief 2026) Back to browse issues page